2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145425
    PAIR2 2771006-54-1 98%
    PAIR2 is a highly selective inhibitor targeting the kinase domain of human IRE1α, with a Ki value of 8.8 nM against human IRE1α. PAIR2 fully occupies the ATP-binding site of the IRE1α kinase domain, partially antagonizes the ribonuclease activity of IRE1α, specifically inhibits regulated IRE1α-dependent decay (RIDD) and its mediated substrate cleavage, while preserving the splicing function of Xbp1 mRNA. PAIR2 also promotes the differentiation of B cells into plasma cells, blocks IRE1α-induced cell apoptosis, and restores the expression of Fgfr2 mRNA in AT2 cells. PAIR2 effectively reaches a steady-state concentration in the lung tissues of Mus musculus, and serves as an important tool for investigating the function of the IRE1α signaling pathway in diseases such as pulmonary fibrosis.
    PAIR2
  • HY-145434
    IL-17 modulator 5 2724206-27-1 98%
    IL-17 modulator 5 (compound 26) is a IL-17 inhibitor, with an IC50 of 1 nM.
    IL-17 modulator 5
  • HY-145474
    17(R)-Resolvin D1 methyl ester 937738-64-2 98%
    17(R)-Resolvin D1 methyl ester is the methyl ester of Resolvin D1 (RvD1) (HY-125527) induced by Aspirin (HY-14654) with the 17R epimer (AT-RvD1). RvD is a regulator of transendothelial migration of human polymorphonuclear leukocytes and an anti-inflammatory agent. The 17R-trihydroxy-4Z of RvD1 also blocks transendothelial migration of human neutrophils (EC50 approximately 30 nM). AT-RvD1 is an effective form that protects against the rapid inactivation of Resolvin D1.
    17(R)-Resolvin D1 methyl ester
  • HY-145475
    Nervonoyl ethanolamide 887405-21-2 98%
    Nervonoyl ethanolamide (NEA) is an endogenous cannabinoid that can act as a presynaptic and postsynaptic neuromodulator. Nervonoyl ethanolamide can also be used in the research of inflammation.
    Nervonoyl ethanolamide
  • HY-145492
    Δ7(Z)-C14-HSL 482598-46-9 98%
    Δ7(Z)-C14-HSL (Compound 12) is an immunosuppressive agent that can inhibit the proliferation of mouse splenic cells with an IC50 of 17 μM. Δ7(Z)-C14-HSL can be used for further studying its potential as a molecular mechanism in TNF-R-driven immune diseases, especially autoimmune diseases such as psoriasis, rheumatoid arthritis, and type 1 diabetes.
    Δ7(Z)-C14-HSL
  • HY-145775
    hIgG-hFc receptor-IN-1 1425051-22-4 98%
    hIgG–hFc receptor-IN-1 (comp 66) is a human immunoglobulin G–human neonatal Fc receptor (hIgG–hFcRn) protein-protein interaction inhibitor, with an IC50 of 2 μM .
    hIgG-hFc receptor-IN-1
  • HY-145829
    Tofacitinib Prodrug-1 98%
    Tofacitinib precursor-1 is an effective and oral active precursor to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib precursor-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity. Tofacitinib precursor-1 is a potential drug candidate for the research of ulcerative colitis.
    Tofacitinib Prodrug-1
  • HY-145831
    sEH/AChE-IN-1 2490589-08-5 98%
    sEH/AChE-IN-1 (Compound 12a) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-1 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-1 has the potential for the research of Alzheimer's disease (AD).
    sEH/AChE-IN-1
  • HY-145832
    sEH/AChE-IN-2 2490589-09-6 98%
    sEH/AChE-IN-2 (Compound 12b) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-2 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-2 has the potential for the research of Alzheimer's disease (AD).
    sEH/AChE-IN-2
  • HY-145853
    GA-O-02 98%
    GA-O-02, a 18β-Glycyrrhetinic acid derivative, is a potent antimicrobial and anti-inflammatory agent. GA-O-02 exerts anti-inflammation through the inhibition of NO, pro-inflammatory cytokines and chemokines. GA-O-02 displays a high antimicrobial activity against Gram-positive bacteria.
    GA-O-02
  • HY-145854
    GA-O-06 98%
    GA-O-06, a 18β-Glycyrrhetinic acid derivative, is a potent antimicrobial and anti-inflammatory agent. GA-O-06 exerts anti-inflammation through the inhibition of NO, pro-inflammatory cytokines and chemokines. GA-O-06 displays a high antimicrobial activity against Gram-positive bacteria.
    GA-O-06
  • HY-145855
    J-1063 2374772-46-8 98%
    J-1063 is a potent, selective and orally active ALK5 inhibitor with an IC50 of 0.039 µM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis.
    J-1063
  • HY-145869
    Anti-inflammatory agent 12 98%
    Anti-inflammatory agent 12 (Compound 2) is a pentacyclic triterpene compound. Anti-inflammatory agent 12 shows a significant bias in the LPS-induced inflammatory response with an IIC50 value of 2.22 μM. Anti-inflammatory agent 12 has the potential for the research of inflammation disease.
    Anti-inflammatory agent 12
  • HY-145870
    Anti-inflammatory agent 13 3032751-32-6 98%
    Anti-inflammatory agent 13 (Compound 3) is a pentacyclic triterpene compound. Anti-inflammatory agent 13 exhibits a considerable inhibitory effect on inflammation models. Anti-inflammatory agent 13 has the potential for the research of either DAMPs or PAMPs triggered inflammation.
    Anti-inflammatory agent 13
  • HY-145874
    Antibacterial agent 76 2902561-25-3 98%
    Antibacterial agent 76 (compound 9) is an antibacterial agent.
    Antibacterial agent 76
  • HY-145875
    Antibacterial agent 77 2902561-28-6 98%
    Antibacterial agent 77 (compound 12) is an antibacterial agent.
    Antibacterial agent 77
  • HY-145876
    Antibacterial agent 78 2902561-42-4 98%
    Antibacterial agent 78 (compound 30) is an antibacterial agent.
    Antibacterial agent 78
  • HY-145878
    Antibacterial agent 80 2902561-34-4 98%
    Antibacterial agent 80 (compound 20) is an antibacterial agent.
    Antibacterial agent 80
  • HY-145884
    BTK-IN-8 2824922-28-1 98%
    BTK-IN-8 is a potent and selective peripheral covalent BTK inhibitor (IC50=0.22 nM; Kd=0.91 nM). BTK-IN-8 has good whole blood CD69 cellular potency (IC50=0.029 µM).
    BTK-IN-8
  • HY-145886
    TLR7/8 antagonist 1 2901020-63-9 98%
    TLR7/8 antagonist 1 (Compound 16c) is a competitive TLR7/8 antagonist with IC50 values of 3.91 μM and 2.19 μM, respectively. TLR7/8 antagonist 1 reduces agonist-induced production of proinflammatory cytokines, including TNFα, IFNγ and IL-1β.
    TLR7/8 antagonist 1
Cat. No. Product Name / Synonyms Application Reactivity